<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127802">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01973075</url>
  </required_header>
  <id_info>
    <org_study_id>22547</org_study_id>
    <nct_id>NCT01973075</nct_id>
  </id_info>
  <brief_title>Genetic Etiology in Premature Ovarian Insufficiency</brief_title>
  <acronym>POI</acronym>
  <official_title>Genetic Etiology in Premature Ovarian Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BEGUM AYDOGAN</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sisli Etfal Training &amp; Research Hospital</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature Ovarian  Insufficiency (POI), first described by Albright in 1942, is defined as
      an increase in Follicle Stimulating Hormone (FSH), an insufficiency of the ovarian function
      leading to an early menopause (&lt;40 years of age).Today, only 35% of POI's etiology can be
      explained. Causes enlightening POI may be enumerated as follows, according to their
      frequency: genetic mutations, autoimmune defects and abnormalities detected on the X
      chromosome.The purpose of the study is to determine the frequency of the genetic
      abnormalities and polymorphisms described above in the POI Turkish population
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Genetic etiology in Premature ovarian Insufficiency</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>In the framework of our project, abnormalities on the X chromosome will be studied by karyotyping, follicle-stimulating hormone receptor (FSHR),nuclear receptor subfamily 5,group A,member 1 (NR5A1),Newborn ovary homeobox gene (NOBOX),Bone morphogenetic protein 15 (BMP15) genes will be analyzed by sequencing and finally repeat size analysis for FMR1 gene will be performed fragment analyses, on 75 POI and 25 healthy control population.Collected data will enable us to determine the frequency of the abnormalities and polymorphisms described above in the POI Turkish population. Patients free of those genetic variants will help us to identify new loci or genes implicated in POI.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Ovarian Insufficiency</condition>
  <condition>Genetic Predisposition to Disease</condition>
  <arm_group>
    <arm_group_label>premature ovarian  Insufficiency</arm_group_label>
    <description>4ml whole blood sample is going to collect from premature ovarian  Insufficiency group for the assessment of genetic abnormalities</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control group</arm_group_label>
    <description>4 ml of whole blood is going to taken from healthy control group</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4ml whole blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients who are admitted to obstetrics and gynecology department
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosed premature ovarian failure patients

          -  20-40 years old female patients

        Exclusion Criteria:

          -  Surgical surgical menopause

          -  Female patients who can't meet the age range criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Engin Oral, Prof,OBGYN</last_name>
    <role>Study Director</role>
    <affiliation>Istanbul University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>begum aydogan, MD,OBGYN</last_name>
    <phone>905063025896</phone>
    <email>begum_aydogan@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istanbul University Cerrahpasa Medical school Obstetrics department</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Engin Oral, Prof,OBGYN</last_name>
      <phone>00902124143000</phone>
      <phone_ext>21414</phone_ext>
      <email>eoral@superonline.com</email>
    </contact>
    <investigator>
      <last_name>begum aydogan, MD,OBGYN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Engin Oral, Prof,OBGYN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seher Basaran, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oya Uyguner, PROF</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>October 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sisli Etfal Training &amp; Research Hospital</investigator_affiliation>
    <investigator_full_name>BEGUM AYDOGAN</investigator_full_name>
    <investigator_title>MD,OBGYN</investigator_title>
  </responsible_party>
  <keyword>Premature Ovarian  Insufficiency (POI)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
